ORIGINAL ARTICLE

Proliferative diabetic retinopathy without preoperative pan-retinal photocoagulation is associated with higher levels of intravitreal IL-6 and postoperative inflammation

Yukihiko Suzuki*, Kobu Adachi, Natsuki Maeda, Reiko Tanabu, Takashi Kudo and Mitsuru Nakazawa

Abstract

Purpose: Intravitreal cytokine levels and differences in the severity of postoperative inflammation in patients with proliferative diabetic retinopathy (PDR) were compared between subjects treated with pan-retinal photocoagulation (PRP) prior to undergoing vitreous surgery and those treated similarly during the surgery.

Subjects and methods: We examined 130 eyes of PDR patients who underwent an initial surgical procedure at Hirosaki University Hospital. A total of 67 out of the 130 eyes were treated with PRP prior to surgery (preoperative group), while 63 underwent similar treatment during surgery (intraoperative group). Vitreous fluid was collected at the start of the vitreous surgical procedure. Following vitrectomy, intraoperative PRP was completed during the surgery in the intraoperative group. This procedure was added to the peripheral part as needed in the preoperative group. The results for the levels of 27 cytokines, including vascular endothelial growth factor (VEGF), were measured using multiplex assays and compared between the groups. For determining postoperative inflammation, eyes in which fibrin was observed for 3 days or longer in the anterior chamber or vitreous cavity were considered to have fibrin deposition. The rate of fibrin deposition was compared between these groups.

Results: Among the vitreous cytokines examined, there was no significant difference in the VEGF levels between the groups (p = 0.70). In contrast, the IL-6 level was significantly higher in the intraoperative group (2813.2 ± 6022.2 vs. 1248.5 ± 1442.2 pg/ml, p = 0.048). Furthermore, the fibrin deposition rate was significantly higher in the intraoperative (44.4%) versus the preoperative group (14.9%) (p = 0.0002).

Conclusion: Severe postoperative inflammation was frequently seen in patients who did not undergo preoperative PRP, which may have been due to the performance of the procedure during the surgery. Moreover, these results may also be associated with a higher level of intravitreal IL-6.

Keywords: Diabetic retinopathy, Vitrectomy, Interleukin-6, Vascular endothelial growth factor

Introduction

In conjunction with an increasing number of patients with type 2 diabetes, diabetic retinopathy (DR) has now become a major health issue worldwide. For treatment of type 2 diabetes, although intensive glycemic control has been reported to be effective in both reducing the risk...
of microvascular complications and the need for retinal photocoagulation [1], strict blood pressure regulation is also known to prevent microvascular complications [2].

Retinal photocoagulation, especially pan-retinal photocoagulation (PRP), has been extensively used to treat patients with diabetic retinopathy in order to prevent progression or avoid resultant loss of vision [3, 4]. Recently, some studies have found that PRP combined with a retinal injection of an anti-vascular endothelial growth factor (VEGF) agent was more effective than a single application of PRP [5] and that patients treated with photocoagulation combined with triamcinolone acetonide [6] had fewer macular edema postoperative complications. As a result, studies have been investigating the importance of photocoagulation, as well as improvements in therapy related to treatments associated with intraocular VEGF and inflammatory cytokines.

It has been suggested that levels of intravitreal interleukin (IL)-6 [7–10], IL-8 [8, 10, 11], TNF-α [7, 9, 12], IL-1β [10], VEGF [8, 13–15], intercellular adhesion molecule (ICAM)-1 [15], and monocyte chemotactic protein (MCP)-1 [8, 16] are higher in patients with proliferative DR (PDR) and/or diabetic macular edema. It is known that VEGF, which is associated with retinal ischemia, can induce retinal angiogenesis and increase vascular permeability. Furthermore, it has also been reported that the severity of DR is related to the level of intravitreal VEGF. Thus, inflammatory cytokines such as IL-6 in addition to VEGF, which increase due to retinal ischemia, may be associated with DR progression. Moreover, it has also been suggested that PRP might prevent this advancement of DR [3, 17, 18].

In addition, it has yet to be determined whether differences in levels of intravitreal cytokines related to the severity of postoperative inflammation exist between patients who have undergone a vitrectomy after PRP and those who received surgery without prior PRP.

Subjects and methods
The present study was performed in accordance with the tenets of the Declaration of Helsinki and approved by the Institutional Review Board of Hirosaki University Graduate School of Medicine (approval number: 2014-353, UMIN: 000022734). Written informed consent was obtained from each patient after receiving an explanation of the nature and possible consequences of taking part in the study.

Patients
We examined 130 eyes in 106 PDR patients (type 2 diabetes) who underwent an initial vitrectomy performed by one of the authors (Y.S.) in the Department of Ophthalmology at the Hirosaki University School of Medicine Hospital between September 2010 to August 2012.

Retinal conditions were classified into four grades: neovascularization (NV), vitreous hemorrhage (VH), fibrovascular proliferation (FVP) and traction retinal detachment (TRD). Based on the severity of PDR, patients with coexisting NV, VH, FVP and/or TRD were classified as TRD, patients with NV, VH and/or FVP were classified as FVP, and patients with NV and VH were classified as VH, respectively.

Patients were excluded from the study if they had received a vitreous injection of an anti-VEGF agent, or had been administered a sub-Tenon or intravitreal triamcinolone acetonide injection within the previous 6 months. In addition, patients diagnosed with neovascular glaucoma or who received PRP and underwent focal photocoagulation within 3 months were excluded. Furthermore, aphakic patients were also excluded.

Patients were divided into two groups. The first group, which contained subjects who underwent a vitrectomy for PDR and then progressed after the PRP for pre-PDR or non-severe PDR, was defined as the preoperative group. The preoperative PRP procedure was previously performed using a spot size of 400–500 μm on the retinal surface, 532 nm, 0.2 ms, 150–200 mW, and 1200–1500 spots divided over three to four times in the preoperative group.

The second group, which was defined as the intraoperative group, included a small number of patients who required a vitrectomy for a vitreous hemorrhage and proliferative membrane that developed following focal photocoagulation for a non-perfusion area. The preoperative focal photocoagulation procedure was previously performed according to the method reported for selective photocoagulation in order to reduce the developing ratio from the pre-PDR to PDR [19]. Coagulation spots were adjusted to 400–500 μm on the retinal surface, with the procedure performed on the non-perfusion area that was confirmed by the fluorescein angiography. The number of coagulation spots ranged from almost 100 to 300. Nearly all of the patients in the intraoperative group were not able to undergo PRP due to the presence of vitreous hemorrhage at the time of their initial visit.

Surgical methods
Undiluted vitreous fluid was collected from PDR patients (130 eyes) at the time of the vitrectomy that was performed at Hirosaki University Hospital using a previously described method [8]. Briefly, vitreous fluid (approximately 0.3 ml) was obtained from each eye prior to staring the fluid irrigation during the initial stage of the vitrectomy procedure. Vitreous samples were
Laboratories, Hercules, CA, U.S.A.). For sample preparation, colony-stimulating factor (GM-CSF), interferon (IFN)-α, interferon (IFN)-γ, MCP-1 (CCL2), MIP-1α (CCL3), MIP-1β (CCL4), IP-10 (CXCL10), platelet-derived growth factor (PDGF), regulated upon activation, normal T cell expressed and secreted (RANTES, CCL5), and VEGF. The measurements of these cytokines were performed using 96-well assay plates and reagent kits according to the procedure provided by the manufacturer.

Evaluation of postoperative inflammation
The severity of postoperative inflammation was analyzed retrospectively using medical records obtained from the consultation on the day after surgery. The presence of fibrin deposition in the anterior chamber or vitreous cavity was confirmed, and then compared between the preoperative and the intraoperative groups. For the examination, postoperative visual acuity, preoperative visual acuity as well as acuity at 6 months after surgery were compared between the groups. Complications that necessitated a reoperation within 1 year after surgery were considered to be postoperative and compared between the groups.

Statistical analysis
The levels of various cytokines including VEGF are presented as means ± standard deviations. We performed Welch T test to compare cytokine expression between the preoperative group and the intraoperative group. Chi-square test and Student T test were used to evaluate statistical differences in preoperative general conditions, preoperative ophthalmological conditions, rate of postoperative fibrin deposition, pre- and postoperative best-corrected visual acuities (logarithm of the minimum angle of resolution, logMAR), and postoperative complications between the groups. For this calculation, the logMAR for counting fingers was defined as 2.0, while hand motion and light perception were defined as 3.0.

Results
Among the 130 eyes of the PDR patients, 67 eyes of 60 patients underwent PRP prior to surgery in the preoperative group, while 63 eyes of 46 patients underwent PRP during surgery in the intraoperative group. There were no significant differences regarding the preoperative age, sex, and diabetes control status between the groups. However, insulin treatment for diabetes was significantly more prevalent in the preoperative group as compared to the intraoperative group (Table 1).

PRP was completed before surgery in all 67 eyes in the preoperative group. In the intraoperative group, photocoagulation was partially performed in 8 (14.5%) and not performed in 55 (85.5%) eyes. The comparison of the the severity of the diabetic retinopathy that required vitrectomy showed that there were no significant differences
for the ratios of retinal neovascularization, vitreous hemorrhage, fibrovascular proliferation, or the traction retinal detachment between the groups (Table 2).

Analysis of the intravitreal cytokines revealed there were no significant differences for the level of VEGF between the preoperative (4885.11 ± 6052.57 pg/ml) and intraoperative (5313.19 ± 6679.82 pg/ml) groups (p = 0.703). In contrast, there was a significantly higher IL-6 level in the intraoperative versus the preoperative group (2813.24 ± 6022.22 vs. 1248.55 ± 1442.20 pg/ml; Welch’s t-test, p = 0.048). Similarly, there was also a significantly higher IL-7 level in the intraoperative group (183.16 ± 216.86 vs. 140.23 ± 160.16; p = 0.024). There were no significant differences observed between the groups regarding the levels of the inflammatory cytokines (Table 3).

Figures 1 and 2 show the results of examinations of the fibrin deposition in the anterior chamber and vitreous cavity, which were used for the evaluation of the postoperative inflammation. The number of eyes with and without fibrin deposition, and days until disappearance of deposition in each group are shown in Fig. 1. Although not common, eyes in which fibrin deposition remained for a long period were noted in the intraoperative group. As shown in Fig. 2, the number of eyes in which fibrin was observed at 3 days postoperatively was significantly smaller in the preoperative group (14.9%) as compared to the intraoperative group (44.4%) (p = 0.0002, Chi-square test).

Table 4 shows the changes in the visual acuity before and after surgery, as well as the postoperative complications in the two groups. In the preoperative group, pre- and postoperative logMAR acuity was 1.47 ± 0.16 and 0.69 ± 0.09, respectively, indicating there was significant improvement (p = 2.15 × 10^{-5}, paired t-test). In contrast, there was no significant difference between before and after surgery for the logMAR acuity in the intraoperative group (0.19 ± 0.18 vs. 0.69 ± 0.14, p = 0.121, paired t-test).

Regarding postoperative complications, vitreous hemorrhage was observed in 3 (4.5%), retinal detachment in 2 (3.0%), and there were no complications in 62 (92.5%) eyes in the preoperative group. In the intraoperative group, vitreous hemorrhage was noted in 2 (3.2%), retinal detachment in 1 (1.6%), and neovascular glaucoma in 1 (1.6%), while there were no complications seen in 60 (95.2%) eyes. Among these complications in the intraoperative group, there was also 1 eye that developed vitreous hemorrhage and which was later complicated with neovascular glaucoma. There was no significant difference regarding the incidence of postoperative complications between the groups (Table 4).

### Table 1 Preoperative general conditions of the preoperative and intraoperative groups

| Age (years old) | Preoperative group 60 cases 67 eyes | Intraoperative group 46 cases 63 eyes |
|-----------------|-------------------------------------|--------------------------------------|
| Gender (male/female) | 56.6 ± 14.6 | 53.1 ± 13.3 |
| DM control level (HbA1c %) | 32 (53%)/28 (47%) | 26 (57%)/20 (43%) |
| DM therapy (diet/drug/insulin) | 7.8 ± 1.9 | 7.9 ± 2.2 |
| 1# p = 0.16, unpaired t-test | 2# p = 0.74, Chi-square test | 3# p = 0.34, unpaired t-test | 4# p = 0.015, Chi-square test |

HbA1c (NGSP)

### Table 2 Preoperative ophthalmological conditions of the preoperative and intraoperative groups

| Photocoagulation (PRP/focal PC/non PC) | Preoperative group 60 cases 67 eyes | Intraoperative group 46 cases 63 eyes |
|--------------------------------------|-------------------------------------|--------------------------------------|
| Retinopathy condition (NV/VH/FVP/TRD) | 67 (100%)/0 (0%)/0 (0%) | 0 (0%)/8 (14.5%)/85 (85.5%) |
| Lens condition (phakia/pseudophakia) | 5 (7%)/35 (52%)/23 (34%)/4 (6%) | 4 (6%)/23 (37%)/21 (33%)/15 (24%) |
| 5# p < 0.001, 6# p = 0.06, 7# p = 0.08, Chi-square test |

NV retinal neovascularization, VH vitreal hemorrhage, FVP fibrovascular proliferation, TRD traction retinal detachment
Retinal photocoagulation techniques, especially PRP, are extensively used for patients with diabetic retinopathy in order to prevent progression and avoid resultant loss of vision [3, 4]. It has been recently reported that PRP using a conventional argon laser was more effective for PDR treatment as compared to that observed when using a pattern scan laser [23]. Moreover, there was a lower incidence of worsening vision reported for this method as compared to vitrectomy [24]. Thus, PRP is now considered to be an important treatment modality for PDR cases. Furthermore, other studies have found that PRP combined with a retinal injection of an anti-VEGF agent was more effective than the single application of PRP [5]. In addition, patients treated with photocoagulation combined with triamcinolone

### Table 3 Intravitreal cytokine levels in the preoperative and intraoperative groups

| Cytokine | Preoperative group | Intraoperative group | p value |
|----------|--------------------|----------------------|---------|
| IL-1β    | 33.36 ± 25.6       | 47.82 ± 58.68        | 0.077   |
| IL-1Ra   | 52.18 ± 74.75      | 51.94 ± 57.84        | 0.984   |
| IL-2     | 39.43 ± 28.49      | 49.49 ± 52.58        | 0.185   |
| IL-4     | 46.66 ± 33.37      | 55.48 ± 61.06        | 0.316   |
| IL-5     | 16.38 ± 15.17      | 36.88 ± 119.00       | 0.179   |
| IL-6     | 1248.55 ± 1442.20  | 2813.24 ± 6022.22    | 0.048   |
| IL-7     | 140.23 ± 160.16    | 183.16 ± 216.86      | 0.024   |
| IL-8     | 2484.05 ± 3815.29  | 2931.02 ± 5054.09    | 0.572   |
| IL-9     | 273.66 ± 253.88    | 291.79 ± 231.32      | 0.671   |
| IL-10    | 691.81 ± 1124.22   | 669.53 ± 1378.81     | 0.920   |
| IL-12    | 167.36 ± 287.64    | 191.15 ± 315.35      | 0.655   |
| IL-13    | 263.98 ± 399.19    | 310.25 ± 547.07      | 0.649   |
| IL-15    | 893.40 ± 417.00    | 995.13 ± 791.16      | 0.366   |
| IL-17    | 269.37 ± 238.59    | 259.26 ± 240.32      | 0.810   |
| IP-10    | 7242.70 ± 6765.15  | 8698.26 ± 8853.63    | 0.297   |
| Eotaxin  | 58.30 ± 44.23      | 68.79 ± 71.69        | 0.323   |
| FGF basic| 369.40 ± 290.56    | 374.41 ± 303.43      | 0.924   |
| G-CSF    | 62.43 ± 49.65      | 61.89 ± 49.48        | 0.074   |
| GM-CSF   | 318.25 ± 360.94    | 364.32 ± 492.66      | 0.544   |
| IFN-γ    | 31.98 ± 25.41      | 40.84 ± 47.92        | 0.195   |
| MCP-1    | 12,935.94 ± 9333.96| 13,931.40 ± 9393.86  | 0.549   |
| MIP-1α   | 172.89 ± 189.55    | 177.05 ± 208.55      | 0.452   |
| MIP-1β   | 1942.38 ± 2209.78  | 1842.21 ± 2224.01    | 0.797   |
| PDGF bb  | 140.66 ± 129.86    | 153.77 ± 218.97      | 0.681   |
| RANTES   | 163.42 ± 271.90    | 260.72 ± 796.88      | 0.360   |
| TNF-α    | 215.16 ± 125.21    | 239.06 ± 173.96      | 0.373   |
| VEGF     | 4885.11 ± 6052.57  | 5313.19 ± 6679.82    | 0.703   |

Welch t test

### Table 4 Postoperative visual acuities and postoperative complications in the preoperative and intraoperative groups

| Complication         | Preoperative group (67 eyes) | Intraoperative group (63 eyes) |
|----------------------|-------------------------------|--------------------------------|
| Visual acuity (logMAR) |                               |                                |
| Preoperative VA       | 1.47 ± 0.16 ± 10−5            | 0.91 ± 0.18 ± 10−2            |
| Postoperative VA (6 months) | 0.69 ± 0.09 ± 10−5          | 0.69 ± 0.14 ± 10−2          |
| Postoperative complications |                         |                                |
| None                  | 62 eyes (92.5%)               | 60 eyes (95.2%)               |
| Vitreous hemorrhage   | 3 eyes (4.5%)                 | 2 eyes (3.2%)                 |
| Retinal detachment    | 2 eyes (3.0%)                 | 1 eye (1.6%)                  |
| Neovascular glaucoma  | 0 eye (0.0%)                  | 1 eye (1.6%)                  |

VA visual acuity
10−5 p = 2.15 × 10−5, 10−2 p = 0.121, paired T test
a Both of vitreous hemorrhage and neovascular glaucoma occurred in one eye

### Discussion

Retinal photocoagulation techniques, especially PRP, are extensively used for patients with diabetic retinopathy in order to prevent progression and avoid resultant loss of vision [3, 4]. It has been recently reported that PRP using a conventional argon laser was more effective for PDR treatment as compared to that observed when using a pattern scan laser [23]. Moreover, there was a lower incidence of worsening vision reported for this method as compared to vitrectomy [24]. Thus, PRP is now considered to be an important treatment modality for PDR cases. Furthermore, other studies have found that PRP combined with a retinal injection of an anti-VEGF agent was more effective than the single application of PRP [5]. In addition, patients treated with photocoagulation combined with triamcinolone

![Fig. 1](image1.png)

*Fig. 1* Eyes with fibrin deposition in the preoperative and intraoperative groups. Eyes with fibrin deposition in the preoperative group (black) and in the intraoperative group (gray) were observed in the postoperative periods

![Fig. 2](image2.png)

*Fig. 2* Rate of fibrin deposition in the preoperative and intraoperative groups. The rate of eyes with fibrin formation at and after 3 days following the surgery in the intraoperative group was higher than that observed in the preoperative group

![Table 3](table3.png)

*Table 3* Intravitreal cytokine levels in the preoperative and intraoperative groups

![Table 4](table4.png)

*Table 4* Postoperative visual acuities and postoperative complications in the preoperative and intraoperative groups
acetonide [6] have also been reported to have fewer incidences of macular edema as a postoperative complication. As these findings demonstrated the importance of photocoagulation, as well as its use as a treatment, recent investigations have begun to examine intraocular VEGF and inflammatory cytokines.

In the present study, our results showed that there was no significant difference in intravitreal VEGF between the intraoperative and the preoperative groups. Generally, since PRP has been shown to reduce the ischemic areas in the retina, it is thought that intravitreal VEGF decreases after PRP. Among the patients that have undergone PRP, some of these subjects developed proliferative changes in the retina and thus, needed to undergo vitrectomy. Furthermore, there was a gradual increase in the intravitreal VEGF concentration that also observed after the PRP. Therefore, we speculated that the intravitreal VEGF levels in the preoperative group cases might also be as high as those seen in the patients without preoperative PRP in the intraoperative group.

In the present study, we retrospectively compared the results of PDR patients who underwent vitrectomy as the PDR progressed (even after undergoing PRP (preoperative group)), with the results for patients who underwent a surgical procedure without prior PRP (intraoperative group). Our findings revealed that among the examined intravitreal cytokines, the levels of IL-6 and IL-7 were significantly higher in the intraoperative versus the preoperative group. In contrast, we found no significant differences for the levels of the other cytokines, including VEGF, which is thought to be associated with PDR severity or the state of retinal ischemia. We also found no differences for IL-8, an inflammatory cytokine or MCP-1, which has been reported to be elevated in PDR patients. Although it has also been reported that a high level of IL-6 is immediately seen after PRP [25], this was not observed in our present cases. This was likely due to the fact that PRP was performed at a relatively long period prior to the surgery in the preoperative group.

The remarkable fibrin formations and the minimal fibrin formations were counted in the present study in order to determine the characteristics of the diabetic retinopathy inflammation. Therefore, the ratio of the postoperative fibrin formation, which was 44.4% in the intraoperative group, was relatively higher than that reported in other previous studies, for example, the 22% reported in study by Diolaiuti et al. [26].

The present study was not randomized but retrospective, thus one could agree that differences in the activity of retinopathy at the time of the vitrectomy are possible. The evaluation of the postoperative inflammation severity demonstrated that the intraoperative group exhibited a tendency for more prolonged inflammation as compared to that observed for the preoperative group. These results are in agreement with the results that showed that the intravitreal level of IL-6, which is an inflammatory cytokine, was higher in the intraoperative group. Furthermore, it is likely that the postoperative inflammation was severe in these patients, as the PRP was performed during the vitreous surgical procedure. Thus, it is reasonable to consider that postoperative inflammation could be increased due to the elevated IL-6 level as well as due to the aggressiveness of the surgical invasion associated with the intraoperative PRP.

The inflammatory cytokine, IL-6, is known to be present in significantly higher concentrations in the vitreous fluid and in the aqueous humor of the anterior chamber in DR patients as compared to that observed in healthy individuals. However, the association of IL-7 with clinical conditions related to DR has yet to be definitively investigated and thus, the potential association currently remains unclear. Even so, a previous report did note that the levels of not only VEGF, but also IL-6, IL-7, MCP-1, and TNF-α in the aqueous humor of the anterior chamber showed a greater decrease after an anti-VEGF intravitreal injection as compared to that observed before the injection, and which was shown to be associated with DR [27]. There were no significant differences in postoperative complications between the preoperative and intraoperative groups. Although the severity of the postoperative inflammation varied, it was not great enough to result in differences in the frequency of complications that would thereby require a reoperation. As for postoperative visual acuity, there were no significant differences observed for preoperative acuity in the intraoperative group, whereas that was a significant improvement in the acuity after the surgery in the preoperative group. In the patients in the preoperative group that had previously undergone PRP, their vision remained relatively stable and was maintained even with the development of retinal neovascularization. However, some of the preoperative group cases might subsequently have needed to undergo a vitrectomy, as vitreous hemorrhage was induced and the proliferative membrane emerged as a result of posterior vitreous detachment. Nevertheless, even in these types of cases, we speculated that their postoperative vision could have been easily restored, as these types of patients are known to have a lower amount of irreversible macular change.

While we cannot conclude that difficulties in achieving a better postoperative vision in patients without PRP prior to surgery was due to severe postoperative inflammation, it is likely that severe inflammation does occur postoperatively in cases without preoperative PRP. Thus, one way to potentially prevent this from occurring is to administer a triamcinolone injection into the vitreous cavity or sub-Tenon at the completion of surgery, along
with the concomitant postoperative intensified use of steroid eye drops, which are considered to be effective in these cases.

Acknowledgements
The authors thank Dr. Yosuke Matsumiya (The University of Tokyo, Tokyo) for his English editing.

Authors’ contributions
All authors read and approved the final manuscript.

Funding
All authors declare that they have no financial disclosure relevant to this paper. Other disclosures: Yukihiko Suzuki (none), Kobu Adachi (none), Natsuki Maeda (none), Reiko Tanabu (none), Takashi Kudo (none), Mitsuru Nakazawa (Santen, Novartis, Alcon Japan)

Availability of data and materials
Not applicable.

Ethics approval and consent to participate
All procedures performed in studies involving human participants were accordance with the ethical standards of the Hiroaki University School of Medicine and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Consent for publication
Informed consent was obtained from all individual participants including in the study.

Competing interests
The authors declare that they have no competing interests.

Received: 30 November 2019 Accepted: 22 May 2020
Published online: 08 June 2020

References
1. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837–53.
2. UKPDS 38: UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 1998;317:703–13.
3. Early Treatment Diabetic Retinopathy Study Research Group. Early photo-coagulation for diabetic retinopathy: ETDRS report no.9. Ophthalmology. 1991;98(5 suppl):767–85.
4. Ferris FL, Davis MD, Aiello LM. Treatment of diabetic retinopathy. N Engl J Med. 1999;341:667–78.
5. Googe J, Brucker AJ, Bressler NM, et al. Randomized trial evaluating short-term effects of intravitreal ranibizumab or triamcinolone acetonide on macular edema after focal/grid laser for diabetic macular edema in eyes also receiving panretinal photocoagulation. Retina. 2011;31:1009–27.
6. Shimura M, Yasuda K, Shiono T. Posterior sub-Tenon’s capsule injection of triamcinolone acetonide prevents panretinal photocoagulation-induced visual dysfunction in patients with severe diabetic retinopathy and good vision. Ophthalmology. 2006;113:381–7.
7. Abu El Asrar AM, Maimone D, Morse PH, et al. Cytokines in the vitreous of patients with proliferative diabetic retinopathy. Am J Ophthalmol. 1992;114:731–4.
8. Suzuki Y, Nakazawa M, Suzuki K, Yamazaki H, Miyagawa Y. Expression profiles of cytokines and chemokines in vitreous fluid in diabetic retinopathy and central retinal vein occlusion. Jpn J Ophthalmol. 2001;55:256–63.
9. Takeuchi M, Sato T, Tanaka A, et al. Elevated levels of cytokines associated with Th2 and Th17 cells in vitreous fluid of proliferative diabetic retinopathy patients. PLoS ONE. 2015;10(9):e0137358. https://doi.org/10.1371/journal.pone.0137358.
10. Feng S, Yu H, Yu Y, et al. Levels of inflammatory cytokines IL-1β, IL-6, IL-8, IL-17A, and TNF-α in aqueous humour of patients with diabetic retinopathy. J Diabet Res. 2018;8546423, 1–6.
11. Hernández C, Segura RM, Fonollosa A, Carrasco E, Francisco G, Simó R. Interleukin-8, monocyte chemoattractant protein-1 and IL-10 in the vitreous fluid of patients with proliferative diabetic retinopathy. Diabet Med. 2005;22:719–22.
12. Demircan N, Safran BG, Solyu M, Ozcan AA, Sizmaz S. Determination of interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye. 2006;20:1366–9.
13. Aiello LP, Avery RL, Arngg PG, et al. Vascular endothelial growth factor in vitreous fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480–7.
14. Adams AP, Miller JW, Bernal M-T, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 1994;118:445–50.
15. Funatsu H, Yamashita H, Sakata K, et al. Vitreous levels of vascular endothelial growth factor and intercellular adhesion molecule 1 are related to diabetic macular edema. Ophthalmology. 2005;112:806–16.
16. Maer R, Weger M, Haller-Schober E-M, et al. Multiplex bead analysis of vitreous and serum concentrations of inflammatory and proangiogenic factors in diabetic patients. Mol Vis. 2008;14:637–43.
17. The Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: clinical application of diabetic retinopathy study (DRS) findings. DRS report number 8. Ophthalmology. 1985;88:583–600.
18. Cordeiro MF, Stanford MR, Phillips PM, et al. Relationship of diabetic microvascular complications to outcome in panretinal photocoagulation treatment of proliferative diabetic retinopathy. Eye. 1997;11:531–6.
19. The Japanese Society of Ophthalmic Diabetology. Subcommittee on the Study of Diabetic Retinopathy Treatment. Multicenter randomized clinical trial of retinal photocoagulation for proliferative diabetic retinopathy. Jpn J Ophthalmol. 2012;56:52–9. https://doi.org/10.1007/s10384-011-0095-2.
20. Suzuki Y, Suzuki K, Yokoi Y, et al. Effects of intravitreal injection of bevacizumab on inflammatory cytokines in the vitreous with proliferative diabetic retinopathy. Retina. 2014;34:165–71.
21. Suzuki Y, Suzuki K, Kudo T, et al. Level of vascular endothelial growth factor in the vitreous fluid of proliferative diabetic retinopathy patients and prognosis after vitrectomy. Ophthalmologica. 2016;236:133–8.
22. Takahashi S, Adachi K, Suzuki Y, et al. Profiles of inflammatory cytokines in the vitreous fluid from patients with rhegmatogenous retinal detachment and their correlations with clinical features. BioMed Res Int. 2016. https://doi.org/10.1155/2016/4256183.
23. Chappelow AV, Tan K, Waheed NK, et al. Panretinal photocoagulation for proliferative diabetic retinopathy: pattern scan laser versus argon laser. Am J Ophthalmol. 2012;153:137–42.
24. Avitabile T, Bonfiglio V, Castiglione F, et al. Severe proliferative diabetic retinopathy treated with vitrectomy or panretinal photocoagulation: a monocenter randomized controlled clinical trial. Can J Ophthalmol. 2011;46:345–51.
25. Shimura M, Yasuda K, Nakazawa T, et al. Panretinal photocoagulation induces pro-inflammatory cytokines and macular thickening in high-risk proliferative diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol. 2009;247:1617–24. https://doi.org/10.1007/s00417-009-1147-x.
26. Diolaiuti S, Senn P, Schmid MK, Job O, Maloca P, Schipper I. Combined lens implantation in severe proliferative diabetic retinopathy. Ophthalmic Surg Lasers Imaging Retina. 2006;37(6):468–74. https://doi.org/10.3928/15428777-20061101-04.
27. Lim SW, Bandala-Sanchez E, Kolic M, et al. The influence of intravitreal ranibizumab on inflammation-associated cytokine concentrations in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci. 2018;59:5382–90. https://doi.org/10.1167/iovs.17-23325.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.